{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:50:10Z","timestamp":1771548610900,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-021-00524-1","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T15:03:37Z","timestamp":1627052617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect\u00ae MM Registry"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8545-3292","authenticated-orcid":false,"given":"Hans C.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina J.","family":"Gasparetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Rifkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian G. M.","family":"Durie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohit","family":"Narang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard R.","family":"Terebelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Toomey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Hardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L.","family":"Omel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazaher","family":"Dhalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafat","family":"Abonour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Connect\u00ae MM Registry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafat","family":"Abonour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"524_CR1","first-page":"423","volume":"11","author":"J Willan","year":"2016","unstructured":"Willan J, Eyre TA, Sharpley F, Watson C, King AJ, Ramasamy K. Multiple myeloma in the very elderly patient: challenges and solutions. Clinical Interv Aging. 2016;11:423\u201335.","journal-title":"Clinical Interv Aging"},{"key":"524_CR2","unstructured":"Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. editors. SEER Cancer Statistics Review, 1975\u20132016. National Cancer Institute; 1975."},{"key":"524_CR3","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1200\/JCO.2014.55.1028","volume":"32","author":"TM Wildes","year":"2014","unstructured":"Wildes TM, Rosko A, Tuchman SA. Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol. 2014;32:2531\u201340.","journal-title":"J Clin Oncol"},{"key":"524_CR4","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.3324\/haematol.2017.173617","volume":"103","author":"F Panitsas","year":"2018","unstructured":"Panitsas F, Kothari J, Vallance G, Djebbari F, Ferguson L, Sultanova M, et al. Treat or palliate: outcomes of very elderly myeloma patients. Haematologica. 2018;103:e32\u2013e34.","journal-title":"Haematologica."},{"key":"524_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1600-0609.2012.01784.x","volume":"89","author":"MA Dimopoulos","year":"2012","unstructured":"Dimopoulos MA, Kastritis E, Delimpasi S, Katodritou E, Hatzimichael E, Kyrtsonis MC, et al. Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era. Eur J Haematol. 2012;89:10\u201315.","journal-title":"Eur J Haematol"},{"key":"524_CR6","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","volume":"117","author":"F Gay","year":"2011","unstructured":"Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117:3025\u201331.","journal-title":"Blood."},{"key":"524_CR7","doi-asserted-by":"publisher","first-page":"5571.","DOI":"10.1182\/blood-2019-131114","volume":"134","author":"JD Gonzalez-Lugo","year":"2019","unstructured":"Gonzalez-Lugo JD, Acuna-Villaorduna A, Heisler J, Goradia N, Cole D, Mejia Saldarriaga M, et al. Real world treatment patterns and toxicity among elderly patients with multiple myeloma. Blood. 2019;134:5571.","journal-title":"Blood."},{"key":"524_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2018-000788","volume":"5","author":"AJ Camm","year":"2018","unstructured":"Camm AJ, Fox KAA. Strengths and weaknesses of \u2018real-world\u2019 studies involving non-vitamin K antagonist oral anticoagulants. Open Heart. 2018;5:e000788.","journal-title":"Open Heart"},{"key":"524_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.clml.2014.12.002","volume":"15","author":"RM Rifkin","year":"2015","unstructured":"Rifkin RM, Abonour R, Terebelo H, Shah JJ, Gasparetto C, Hardin J, et al. Connect MM registry: the importance of establishing baseline disease characteristics. Clin Lymphoma Myeloma Leukemia. 2015;15:368\u201376.","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"524_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3\u20139.","journal-title":"Leukemia"},{"key":"524_CR11","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jgo.2020.03.005","volume":"11","author":"MA Fiala","year":"2020","unstructured":"Fiala MA, Foley NC, Zweegman S, Vij R, Wildes TM. The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma. J Geriatr Oncol. 2020;11:1274\u20138.","journal-title":"J Geriatr Oncol"},{"key":"524_CR12","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.ejca.2010.02.022","volume":"46","author":"AG Pallis","year":"2010","unstructured":"Pallis AG, Fortpied C, Wedding U, Van Nes MC, Penninckx B, Ring A, et al. EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer. 2010;46:1502\u201313.","journal-title":"Eur J Cancer"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00524-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00524-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00524-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:21:49Z","timestamp":1669918909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00524-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":12,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["524"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00524-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"14 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.C.L. consultancy\/advisory role with Adaptive Biotechnologies, Amgen, Celgene, a Bristol Myers Squibb Company, Genentech, GlaxoSmithKline, Janssen, Sanofi, and Takeda Pharmaceutical; research funding from Amgen, Celgene, a Bristol Myers Squibb Company, Daiichi Sankyo, Eutropics Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutical, Regeneron, and Takeda Pharmaceutical; S.A. consultancy\/advisory role with Takeda, Novartis, Celgene, a Bristol Myers Squibb Company, Amgen; research funding from Pharmacyclics LLC, an AbbVie Company; C.J.G. receives honoraria from Janssen, Bristol Myers Squibb, Celgene, a Bristol Myers Squibb Company, and Takeda; consultancy\/advisory role with Janssen, Bristol Myers Squibb, and Celgene, a Bristol Myers Squibb Company; travel, accommodations, or other expenses paid by Janssen, Bristol Myers Squibb, and Celgene, a Bristol Myers Squibb Company; research funding from Celgene, a Bristol Myers Squibb Company; S.J. consultancy\/advisory role with Celgene, a Bristol Myers Squibb Company, Bristol Myers Squibb, Novartis, Merck; speakers\u2019 bureau for MMRF and Medicom; R.M.R. consultancy\/advisory role with Amgen, Boehringer Ingelheim, Celgene, a Bristol Myers Squibb Company, EMD Serono, Sandoz, and Takeda; stock with McKesson; B.G.M.D. consultancy\/advisory role with Takeda and Janssen; M.N. consultancy\/advisory role with and speakers\u2019 bureau for Celgene, a Bristol Myers Squibb Company; speakers\u2019 bureau for Janssen; H.R.T. consultancy\/advisory role with Celgene, a Bristol Myers Squibb Company; speakers\u2019 bureau for Janssen, Takeda, and Pharmacyclics LLC, an AbbVie Company; K.T. consultancy\/advisory role with Celgene, a Bristol Myers Squibb Company; J.W.H. consultancy\/advisory role with Celgene, a Bristol Myers Squibb Company; L.W. consultancy\/advisory role with EveryFit, Gilead, and Janssen; J.L.O. receives honoraria from Takeda Oncology and Celgene, a Bristol Myers Squibb Company; board of directors\/advisory committee for Takeda Oncology and Celgene, a Bristol Myers Squibb Company; M.D. employment and stock ownership at Bristol Myers Squibb; L.L. employment at Bristol Myers Squibb; P.J. employment at Bristol Myers Squibb; R.A. steering committee member for and research funding from Celgene, a Bristol Myers Squibb Company, and Takeda; research funding for Prothena.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"134"}}